Ecnoglutide
Also called XW003
Subcutaneous (under the skin)Human study reference
Research reference
Human study
SLIM-1 phase 3 trial
Once-weekly study injections; separate 1.2, 1.8 and 2.4 mg target groups
Primary body-weight assessment at week 40
Ecnoglutide phase 3 trial (2025) ↗When results may show
- When change was measured
- The primary endpoint was weight change at week 40, not immediate appetite change.
- When to assess
- Primary body-weight assessment at week 40
- Conditions and limitations
- 664 adults with overweight or obesity at 36 Chinese sites. Target doses are not a verified starter or current product label. Do not reconstruct the escalation from the abstract.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Sources: Ecnoglutide phase 3 trial (2025)
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Vial arithmetic
Published research contexts for Ecnoglutide describe 1.2–2.4 mg per administration. Descriptive only, not a recommendation.
Modelled level — once a week
1× is the peak after a single dose.
- Steady-state peak
- 1.57× single dose
- Time to steady state
- 25.0days
- Administrations
- 1/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Ecnoglutide phase 3 trial (2025)Target doses are not a verified starter or current product label. Do not reconstruct the escalation from the abstract.
Next steps
Ecnoglutide beginner guideOpen Ecnoglutide planning worksheetEstimate Ecnoglutide vial costTrack Ecnoglutide notes